FindTrial
Sign In

FK506

DRUG11 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Baylor College of Medicine, Nanjing University School of Medicine, Astellas Pharma Inc, Zhi-Hong Liu, M.D.

Conditions

Anemia, Sickle CellChronic PainConjunctivitisFSGSGraft FailureHematologic MalignancyHemoglobin SC DiseaseHemoglobinopathies

Phase 1

Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H
TerminatedNCT00048399
Baylor College of MedicineGraft Failure
Start: 2000-12-31End: 2003-10-31Target: 40Updated: 2020-01-18
Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases
TerminatedNCT00056979
Baylor College of MedicineInherited Metabolic Storage Diseases
Start: 2002-06-30End: 2003-06-30Updated: 2015-09-23
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
CompletedNCT00056966
Baylor College of MedicineHematologic Malignancy
Start: 2002-11-30End: 2006-12-31Updated: 2012-06-29

Phase 2

Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
TerminatedNCT00034528
National Institute of Allergy and Infectious Diseases (NIAID)Anemia, Sickle Cell, Hemoglobinopathies, Hemoglobin SC Disease +2
Start: 2001-09-30End: 2003-11-30Updated: 2013-05-01
Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies
TerminatedNCT00040417
Baylor College of MedicineHemoglobinopathy, Sickle Cell Anemia, Thalassemia
Start: 2000-08-31End: 2003-11-21Target: 15Updated: 2020-01-18

Phase 3

Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
CompletedNCT00567918
Astellas Pharma IncConjunctivitis, Keratoconjunctivitis
Start: 2004-05-31End: 2008-01-31Updated: 2008-04-04
Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
CompletedNCT00567762
Astellas Pharma IncConjunctivitis, Keratoconjunctivitis
Start: 2004-02-29End: 2004-09-30Updated: 2014-09-01

Unknown Phase

To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN
CompletedNCT00302549
Nanjing University School of MedicineLupus Nephritis
Start: 2004-05-31End: 2006-02-28Updated: 2010-05-27
Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid
CompletedNCT01161459
Zhi-Hong Liu, M.D.Idiopathic Membranous Nephropathy
Start: 2010-06-30End: 2013-10-31Target: 100Updated: 2014-06-02
The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis
TerminatedNCT01451489
Nanjing University School of MedicineFSGS
Start: 2011-10-13End: 2016-10-29Updated: 2017-03-27
Investigation of Pain Incidence After FK506 Immunosuppressive Therapy in Liver Transplantation Patients
RecruitingNCT04559048
The Second Hospital of TangshanChronic Pain, Liver Transplantation
Start: 2019-09-15End: 2024-06-30Target: 300Updated: 2024-01-22